MACROGENICS, INC. Prepaid Expense and Other Assets, Current
MACROGENICS, INC. (MGNX) had Prepaid Expense and Other Assets, Current of $4.21 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-14
- 2026-06-30: Prepaid Expense and Other Assets, Current $4.21M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $8.37M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $7.22M; Prepaid Expense and Other Assets, Current as first filed $8.74M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $7.71M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $4.21M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $8.37M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $7.22M 10-Q · filed 2026-08-14 | $8.74M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $7.71M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $6.65M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $7.98M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $11.51M 10-Q · filed 2025-11-12 | |
| 2024-09-30 | $9.84M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $9.27M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $9.87M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $9.95M 10-Q · filed 2024-11-05 | |
| 2023-09-30 | $8.51M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $6.47M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $9.72M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $10.16M 10-Q · filed 2023-11-06 | |
| 2022-09-30 | $9.27M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $12.56M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $14.71M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $21.17M 10-Q · filed 2022-11-03 | |
| 2021-09-30 | $18.06M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $17.96M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $18.22M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $16.98M 10-Q · filed 2021-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |